Nurix Shares Gain On Encouraging Early Data From Blood Cancer Trial

by Vandana Singh, Benzinga Editor

October 27, 2021 1:07 PM | 1 min read |

Nurix Therapeutics Inc NRIX announced initial data from Phase 1a trial of NX-2127 in relapsed or refractory B cell malignancies.
Initial data from the first two completed cohorts of 100 mg and 200 mg, which included six patients, showed BTK levels in peripheral blood significantly decreased in all patients starting on day 1 and remained suppressed throughout the dosing period.
BTK degradation exceeded 80% at a steady state in the first dose cohort and 90% in the second dose cohort.
The Company plans to complete the dose-escalation portion of the study and move into the expansion phase in selected cancers in the 1H of 2022.
Price Action: NRIX shares are up 21% at $35.04 during the market session on the last check Wednesday

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.